Browse by author
Lookup NU author(s): Dr Tevfik Dorak
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
We explored the influence of the major CCR5 promoter or coding region variants as haplotypes and genotypes in a cohort of 250 chronically infected HCV patients receiving combined interferon/ ribavirin therapy. No haplotype, including the D32-bearing haplotype (G*2) reportedly associated in homozygotes with high HCV viral load (VL), showed a similar effect. Patients with genotype C/G*2 showed slightly lower median VL (p = 0.05). Neither the G*2 haplotype nor the C/G*2 genotype influenced viral dynamics during the initial 12 wk of treatment (p = 0.53). The genotype E/E was more frequent among sustained responders (15.5%) than non-responders (7.8%), and VL declined further among E/E homozygotes during the initial 12 wk of treatment, particularly those with HCV genotype 1 (p = 0.016). Differential receptor expression due to E/E homozygosity in HCV infection remains to be confirmed.
Author(s): Dorak MT; Folayan GO; Niwas S; van Leeuwen DJ; Yee LJ; Tang J; Kaslow RA
Publication type: Article
Publication status: Published
Journal: Immunologic Research
Year: 2002
Volume: 26
Issue: 1-3
Pages: 167-175
ISSN (print): 0257-277X
ISSN (electronic): 1559-0755
Publisher: Humana Press, Inc.
URL: http://dx.doi.org/10.1385/IR:26:1-3:167
DOI: 10.1385/IR:26:1-3:167
PubMed id: 12403355
Altmetrics provided by Altmetric